Skip to content

Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells

The Effect of Intrauterine Injection of Human Chorionic Gonadotrophins (hCG) on the Endometrial T-regulatory Cells and the Electronmicroscopic Endometrial Characteristics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01064219
Enrollment
20
Registered
2010-02-08
Start date
2010-02-28
Completion date
2010-12-31
Last updated
2013-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

hCG, Treg cells, implantation, pinopodes, endometrium

Brief summary

Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation. It has been demonstrated that regulatory T cells expand during pregnancy. hCG was found to be secreted by the embryo immediately after fertilization and has chemoattractant properties to Treg cells.

Detailed description

Aim of the work: To study the effect of intrauterine injection of human chorionic gonadotrophin on the endometrial T regulatory cells (Treg cells)and the electromicroscopic endometrial characteristics. Background: It has been demonstrated that regulatory T cells expand during pregnancy and are present at the feto-maternal interface at very early stages in pregnancy. Rational: Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation. Methods: Intrauterine injection of 100 IU hCG will be done followed by endometrial biopsy to check for Treg cells and pinopodes.

Interventions

intrauterine injection of 100 IU hCG followed by endometrial biopsy .

Sponsors

The Egyptian IVF-ET Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Male factor infertility * Ovulatory factor infertility * Unexplained infertility * Female age less than 39

Exclusion criteria

* Azoospermia * Tubal factor infertility * Pelvic endometriosis

Design outcomes

Primary

MeasureTime frame
the presence of Treg cells and pinopodes in the endometrium4 weeks

Secondary

MeasureTime frame
pregnancy rate4 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026